Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA

Essi Myrsky, Sergio Caja, Zsofi Simon-Vecsei, Ilma R. Korponay-Szabo, Cristina Nadalutti, Russell Collighan, Alexandre Mongeot, Martin Griffin, Markku Mäki, Katri Kaukinen, Katri Lindfors

Research output: Contribution to journalArticle

Abstract

Celiac disease is characterized by the presence of specific autoantibodies targeted against transglutaminase 2 (TG2) in untreated patients' serum and at their production site in the small-bowel mucosa below the basement membrane and around the blood vessels. As these autoantibodies have biological activity in vitro, such as inhibition of angiogenesis, we studied if they might also modulate the endothelial barrier function. Our results show that celiac disease patient autoantibodies increase endothelial permeability for macromolecules, and enhance the binding of lymphocytes to the endothelium and their transendothelial migration when compared to control antibodies in an endothelial cell-based in vitro model. We also demonstrate that these effects are mediated by increased activities of TG2 and RhoA. Since the small bowel mucosal endothelium serves as a "gatekeeper" in inflammatory processes, the disease-specific autoantibodies targeted against TG2 could thus contribute to the pathogenic cascade of celiac disease by increasing blood vessel permeability.
LanguageEnglish
Pages3375-85
Number of pages11
JournalCellular and Molecular Life Sciences
Volume66
Issue number20
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Capillary Permeability
Celiac Disease
Autoantibodies
Immunoglobulin A
Endothelium
Blood Vessels
Permeability
Transendothelial and Transepithelial Migration
Basement Membrane
Mucous Membrane
Endothelial Cells
Lymphocytes
In Vitro Techniques
transglutaminase 2
Antibodies
Serum

Keywords

  • celiac disease
  • disease-specific autoantibodies
  • transglutaminase 2
  • vascular permeability
  • RhoA activation

Cite this

Myrsky, Essi ; Caja, Sergio ; Simon-Vecsei, Zsofi ; Korponay-Szabo, Ilma R. ; Nadalutti, Cristina ; Collighan, Russell ; Mongeot, Alexandre ; Griffin, Martin ; Mäki, Markku ; Kaukinen, Katri ; Lindfors, Katri. / Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA. In: Cellular and Molecular Life Sciences. 2009 ; Vol. 66, No. 20. pp. 3375-85.
@article{595db8ebcda84691b23d4bc6dff501e6,
title = "Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA",
abstract = "Celiac disease is characterized by the presence of specific autoantibodies targeted against transglutaminase 2 (TG2) in untreated patients' serum and at their production site in the small-bowel mucosa below the basement membrane and around the blood vessels. As these autoantibodies have biological activity in vitro, such as inhibition of angiogenesis, we studied if they might also modulate the endothelial barrier function. Our results show that celiac disease patient autoantibodies increase endothelial permeability for macromolecules, and enhance the binding of lymphocytes to the endothelium and their transendothelial migration when compared to control antibodies in an endothelial cell-based in vitro model. We also demonstrate that these effects are mediated by increased activities of TG2 and RhoA. Since the small bowel mucosal endothelium serves as a {"}gatekeeper{"} in inflammatory processes, the disease-specific autoantibodies targeted against TG2 could thus contribute to the pathogenic cascade of celiac disease by increasing blood vessel permeability.",
keywords = "celiac disease, disease-specific autoantibodies, transglutaminase 2, vascular permeability, RhoA activation",
author = "Essi Myrsky and Sergio Caja and Zsofi Simon-Vecsei and Korponay-Szabo, {Ilma R.} and Cristina Nadalutti and Russell Collighan and Alexandre Mongeot and Martin Griffin and Markku M{\"a}ki and Katri Kaukinen and Katri Lindfors",
year = "2009",
month = "10",
doi = "10.1007/s00018-009-0116-1",
language = "English",
volume = "66",
pages = "3375--85",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "20",

}

Myrsky, E, Caja, S, Simon-Vecsei, Z, Korponay-Szabo, IR, Nadalutti, C, Collighan, R, Mongeot, A, Griffin, M, Mäki, M, Kaukinen, K & Lindfors, K 2009, 'Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA' Cellular and Molecular Life Sciences, vol. 66, no. 20, pp. 3375-85. https://doi.org/10.1007/s00018-009-0116-1

Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA. / Myrsky, Essi; Caja, Sergio; Simon-Vecsei, Zsofi; Korponay-Szabo, Ilma R.; Nadalutti, Cristina; Collighan, Russell; Mongeot, Alexandre; Griffin, Martin; Mäki, Markku; Kaukinen, Katri; Lindfors, Katri.

In: Cellular and Molecular Life Sciences, Vol. 66, No. 20, 10.2009, p. 3375-85.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA

AU - Myrsky, Essi

AU - Caja, Sergio

AU - Simon-Vecsei, Zsofi

AU - Korponay-Szabo, Ilma R.

AU - Nadalutti, Cristina

AU - Collighan, Russell

AU - Mongeot, Alexandre

AU - Griffin, Martin

AU - Mäki, Markku

AU - Kaukinen, Katri

AU - Lindfors, Katri

PY - 2009/10

Y1 - 2009/10

N2 - Celiac disease is characterized by the presence of specific autoantibodies targeted against transglutaminase 2 (TG2) in untreated patients' serum and at their production site in the small-bowel mucosa below the basement membrane and around the blood vessels. As these autoantibodies have biological activity in vitro, such as inhibition of angiogenesis, we studied if they might also modulate the endothelial barrier function. Our results show that celiac disease patient autoantibodies increase endothelial permeability for macromolecules, and enhance the binding of lymphocytes to the endothelium and their transendothelial migration when compared to control antibodies in an endothelial cell-based in vitro model. We also demonstrate that these effects are mediated by increased activities of TG2 and RhoA. Since the small bowel mucosal endothelium serves as a "gatekeeper" in inflammatory processes, the disease-specific autoantibodies targeted against TG2 could thus contribute to the pathogenic cascade of celiac disease by increasing blood vessel permeability.

AB - Celiac disease is characterized by the presence of specific autoantibodies targeted against transglutaminase 2 (TG2) in untreated patients' serum and at their production site in the small-bowel mucosa below the basement membrane and around the blood vessels. As these autoantibodies have biological activity in vitro, such as inhibition of angiogenesis, we studied if they might also modulate the endothelial barrier function. Our results show that celiac disease patient autoantibodies increase endothelial permeability for macromolecules, and enhance the binding of lymphocytes to the endothelium and their transendothelial migration when compared to control antibodies in an endothelial cell-based in vitro model. We also demonstrate that these effects are mediated by increased activities of TG2 and RhoA. Since the small bowel mucosal endothelium serves as a "gatekeeper" in inflammatory processes, the disease-specific autoantibodies targeted against TG2 could thus contribute to the pathogenic cascade of celiac disease by increasing blood vessel permeability.

KW - celiac disease

KW - disease-specific autoantibodies

KW - transglutaminase 2

KW - vascular permeability

KW - RhoA activation

UR - http://www.scopus.com/inward/record.url?scp=70350502301&partnerID=8YFLogxK

UR - https://link.springer.com/article/10.1007%2Fs00018-009-0116-1

U2 - 10.1007/s00018-009-0116-1

DO - 10.1007/s00018-009-0116-1

M3 - Article

VL - 66

SP - 3375

EP - 3385

JO - Cellular and Molecular Life Sciences

T2 - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 20

ER -